Revvity reports Q2 results on July 30 against a backdrop where short sellers have been quietly reducing pressure — but the stock's one-day stumble and mixed analyst posture keep the debate alive.
The short-side story has shifted meaningfully over the past month. Short interest has dropped roughly 12% in 30 days, falling to 6.6% of the free float, with the most recent daily readings continuing to tick lower. That retreat has coincided with a loosening borrow market: availability has climbed to 379% — nearly double what it was a week ago and well above the 52-week floor of 156% — meaning shares are plentiful for anyone still wanting to establish a position. Borrowing costs remain negligible at 0.55%. The ORTEX short score has also eased from a recent high of 59.2 on July 17 to 54.3, confirming the directional shift. Options positioning is calm rather than charged: the put/call ratio of 0.44 runs only modestly above its 20-day average and nowhere near the defensive extremes seen in June. Taken together, the lending and derivatives markets are not signaling acute stress heading into the print.
The analyst community offers a more divided picture. Evercore ISI lifted its target to $125 on July 6 while maintaining an Outperform — the most bullish recent move among active coverage. Bernstein reinstated coverage at Market Perform with a $115 target in late June. JP Morgan sits at Neutral with a $90 target, the most cautious on the Street, while TD Cowen holds a Buy and a $120 target. The consensus mean sits near $117, roughly 6% above the current price of $110.47. Bulls point to the strategic pivot from TST to IGRA testing, which is projected to add several hundred basis points of annual growth, plus momentum in the Signals software platform and US autoimmune market share gains. Bears flag persistent China revenue pressure — total China exposure expected near 7% of revenue in 2025 and still declining — alongside broader life sciences funding headwinds that could weigh on customer demand. Forward earnings revisions have been sharply positive (ranking in the 95th percentile on 12-month forward EPS growth), though near-term EV/EBITDA compression over the past month hints at valuation-multiple pressure despite the improving earnings outlook.
The prior two earnings events are worth noting. The May 2026 Q1 print produced a 14.5% single-day gain and held most of that move over the following week — a powerful reaction that likely accelerated the short-covering seen since. Before that, the April 2026 print delivered a more modest 5% move on the day but a 20% gain over the subsequent five sessions. That pattern of earnings-driven relief rallies explains in part why short sellers have been trimming rather than adding. Peers were broadly weaker on Friday — BRKR fell 2.7% and WAT slid 2% on the day — suggesting the sector itself faced headwinds even as RVTY dipped 2.4%, not an outsider move but consistent with the group.
The July 30 print will test whether Revvity's IGRA-driven growth thesis is translating into revenue and margin improvement at a pace that justifies a stock trading near the top of its post-rebrand range, and whether China-driven revenue erosion is stabilising or deepening.
See the live data behind this article on ORTEX.
Open RVTY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Revvity heads into Monday's earnings call with short interest down 4.6% over the past month and borrowing costs soft. Analyst sentiment has cooled sharply since February's post-earnings optimism gave way to April…
